Skip to main content

Headlands Research Further Expands its Leading Clinical Research Site Network by Acquiring Peninsula Research Associates

Written by Customer Service on . Posted in Mergers And Acquisitions.

SAN FRANCISCO, June 30, 2022 (GLOBE NEWSWIRE) — Headlands Research announced today the acquisition of Peninsula Research Associates (PRA) of Rolling Hills, CA, continuing the growth of its leading integrated network of clinical trial sites. Terms of the transaction were not disclosed.

The addition of PRA augments Headlands’ clinical research capabilities in the allergy and asthma therapeutic areas, as well as extends its expertise into pediatric studies. In addition, PRA has a well-earned representation as a leading clinical research site for conducting high-quality research studies in the vaccine space, which is a Headlands’ Center of Excellence.

The acquisition of PRA advances Headlands’ mission of profoundly impacting the clinical trial process as well as extending its global network of clinical trial sites further within California, beyond its current San Diego and Riverside locations, as well as its headquarters in the San Francisco Bay Area.

“We are extremely excited to welcome Dr. Lawrence Sher and PRA’s outstanding research team to the Headlands network,” said Mark Blumling, CEO and Founder of Headlands Research. “Together, we look forward to significantly expanding research activity and improving the lives of clinical trial participants throughout Southern California.”

About Headlands Research

Headlands Research is a globally integrated clinical trial site organization with a mission to profoundly change the clinical trials process. Its group of exceptional sites focuses on large volume recruitment of diverse and specialty patient populations while delivering the highest quality data. Headlands Research’s principal investigators are proven industry leaders in their fields with expertise in a wide variety of indications. Utilizing expert recruitment strategies and access to diverse patients through its site databases and physician partnerships. Based in San Francisco and backed by KKR & Co. Inc (NYSE: KKR), Headlands aims to ensure that high quality therapeutics are made available to patients who can benefit from them. Headlands Research has successfully completed more than 5000 clinical trials. Additional information about the company is available at www.headlandsresearch.com

Media Contact:
Lauren Chazal
Headlands Research
media@headlandsresearch.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.